PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573895
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1573895
Multiple Myeloma Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Multiple Myeloma Therapeutics Market held USD 25.4 billion in 2023 and will grow at 6.4% CAGR from 2024 to 2032, propelled by the increasing incidence of multiple myeloma, coupled with substantial advancements in treatment options. Rising awareness and improved diagnostic techniques have led to earlier detection and higher reported cases. Also, the development of innovative therapies, such as targeted treatments and immunotherapies, has transformed patient outcomes, providing more effective and personalized options. As healthcare providers adopt these advancements and more patients seek treatment, the demand for multiple myeloma therapeutics will continue to expand considerably.
The multiple myeloma therapeutics industry is divided based on treatment type, route of administration, disease type, end-use, and region.
The targeted therapy segment witnessed USD 8.7 billion in 2023, owing to its ability to precisely attack cancer cells while sparing healthy tissues. These therapies, which include monoclonal antibodies and proteasome inhibitors, have demonstrated significant efficacy in improving patient outcomes and prolonging survival rates. As ongoing research continues to unveil new targets and combinations, the appeal of targeted therapies is set to increase. Their rising adoption in clinical settings further solidifies this segment's dominant position in the market.
The hospitals segment will expand to USD 24.3 billion by 2032, primarily due to their role as primary treatment centers for cancer patients. Hospitals provide comprehensive care, including advanced diagnostic tools, specialized treatment regimens, and access to multidisciplinary teams of healthcare professionals. As the complexity of multiple myeloma therapies increases, hospitals are well-equipped to manage and administer these treatments effectively. Besides, the rising number of cancer patients seeking treatment in hospital settings further drives the demand for therapeutics in this segment.
North America multiple myeloma therapeutics market will demonstrate a 6.2% CAGR and register USD 20.4 billion by 2032, driven by advanced healthcare infrastructure and high rates of cancer diagnosis. The region benefits from sizable investments in research and development, leading to the introduction of innovative therapies. Furthermore, a growing aging population and increased awareness about multiple myeloma contribute to higher treatment demand. Access to specialized medical centers and comprehensive health insurance coverage further enhance patient access to therapies, making North America a notable contributor to the global market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of multiple myeloma
- 3.2.1.2 Improved diagnostic technologies
- 3.2.1.3 Patient awareness and education
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High treatment costs
- 3.2.2.2 Adverse effects associated with treatment
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Chemotherapy
- 5.3 Targeted therapy
- 5.4 Immunomodulating agents
- 5.5 Stem cell transplantation
- 5.6 Radiation therapy
- 5.7 Other treatment types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Active multiple myeloma
- 7.3 Smoldering multiple myeloma
Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Specialty clinics
- 8.4 Homecare settings
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Service Provider
- 10.1.1 Cleveland Clinic
- 10.1.2 Dana-Farber Cancer Institute, Inc.
- 10.1.3 Mayo Foundation for Medical Education and Research (MFMER)
- 10.1.4 MD Anderson Cancer Center
- 10.1.5 Memorial Sloan Kettering Cancer Center
- 10.2 Medication Manufacturers
- 10.2.1 AbbVie Inc.
- 10.2.2 Amgen Inc.
- 10.2.3 Bristol-Myers Squibb Company.
- 10.2.4 Glenmark Pharmaceuticals Ltd.
- 10.2.5 Johnson and Johnson Services, Inc
- 10.2.6 Merck and Co, Inc.
- 10.2.7 Novartis AG
- 10.2.8 Sanofi S.A.
- 10.2.9 Takeda Pharmaceutical Company Limited
